Ignac Fogelman

Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.

I. Fogelman, P. Ryan, T. Gibson, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Goserelin (Zoladex) and the skeleton

I. Fentiman, J. Studd, I. Fogelman, 1994, British journal of obstetrics and gynaecology.

The relationship between gonadotrophins, gonadal hormones and bone mass in men

A. Wierzbicki, I. Fogelman, A. Dolan, 2008, Clinical endocrinology.

Screening for Osteopenia and Osteoporosis: Do the Accepted Normal Ranges Lead to Overdiagnosis?

G. Blake, I. Fogelman, A.I.H. Ahmed, 1997, Osteoporosis International.

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.

J. Reginster, I. Fogelman, C. Ribot, 2000, The Journal of clinical endocrinology and metabolism.

Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD).

M. Shearer, P. Chowienczyk, A. Wierzbicki, 2011, Bone.

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.

B. Evans, C. Elford, I. Fogelman, 2015, Cytokine.